| Identification | |
| Name: | Alendronate sodium |
| Synonyms: | (4-Amino-1-hydroxy-1-phosphono-butyl)phosphonic acid; sodium;Fosamax (TN);Alendronate sodium hydrate;sodium [4-amino-1-hydroxy-1-(hydroxy-oxido-phosphoryl)butyl]phosphonic acid trihydrate;Alendronate sodium hydrate (JAN);Alendronate Sodium (Fosamax);Alendronate Sodium BP;G-704,650;MK-217; |
| CAS: | 121268-17-5 |
| Molecular Formula: | C4H12NNaO7P2.3(H2O) |
| Molecular Weight: | 249.096042 |
| InChI: | InChI=1S/C4H13NO7P2/c5-3-1-2-4(6,13(7,8)9)14(10,11)12/h6H,1-3,5H2,(H2,7,8,9)(H2,10,11,12) |
| Molecular Structure: |  |
| Properties | |
| Density: | 1.857g/cm3 |
| Water Solubility: | Water, double-distilled: 10 mg/mL |
| Solubility: | Water, double-distilled: 10 mg/mL |
| Appearance: | White Crystalline Solid |
| Specification: |
?Alendronate sodium , its cas register number is 121268-17-5. It also can be called Fosamax ; Monosodium alendronate ; Alendronic acid monosodium salt ; Fosalan ; Alendros ; Bifosa ; NeoBon ; 4-Amino-1-hydroxybutylidene-1,1-bisphosphonic acid monosodium salt ; and Osteovan .?It is marketed alone as well as in combination with vitamin D, and Merck's U.S. patent on alendronate expired in 2008 and Merck lost a series of appeals to block a generic version of the drug from being certified by the U.S. Food and Drug Administration (FDA).?Alendronate inhibits osteoclast-mediated bone-resorption. |
| Color: | white |
| Usage: | Alendronate sodium (CAS NO.121268-17-5) is a bisphosphonate drug used for osteoporosis and several other bone diseases. And it used for prophylaxis and in treatment of female and male osteoporosis. It has been used for prevention and treatment of corticosteroid-associated osteoporosis together with supplements of calcium and vitamin D, and used for paget's disease. |
| Safety Data | |
 |
|
